stockportfolio.pro
Prime Medicine, Inc. (PRME)
Healthcare · Biotechnology · NasdaqGM
Prime Medicine, Inc. revenue & earnings — last 6 fiscal years
| Metric | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $5.21M | $0 | $0 | $0 | $2.98M | $4.63M |
| Gross profit | — | — | — | — | — | — |
| Net income | $-3.41M | $-165.37M | $-121.82M | $-198.13M | $-195.88M | $-201.14M |
| Net margin | -65.5% | — | — | — | -6566.6% | -4342.4% |
Source: Prime Medicine, Inc. SEC filings (10-K).
Explore 6 years of Prime Medicine, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track PRME in your portfolio →
Prime Medicine, Inc. financial history by metric
About Prime Medicine, Inc.
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Prime Medicine, Inc. — frequently asked questions
What is Prime Medicine, Inc.'s revenue?
Prime Medicine, Inc. (PRME) reported revenue of $4.63M for fiscal year 2025, up 55.3% from the prior year, according to its SEC filings.
Is Prime Medicine, Inc. profitable?
No — PRME reported a net loss of $-201.14M in fiscal 2025.
What is PRME's P/E ratio?
Prime Medicine, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Prime Medicine, Inc. growing?
PRME's revenue grew at roughly -2.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Prime Medicine, Inc. have?
As of fiscal year 2025, PRME carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Prime Medicine, Inc.'s market cap?
Prime Medicine, Inc. (PRME) has a market capitalization of about $500.31M, based on the latest data in our nightly-refreshed cache.
When does Prime Medicine, Inc.'s fiscal year end?
PRME's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Prime Medicine, Inc.'s official SEC filings (10-K and 10-Q), covering 6 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.